The cia Gene: Structure, Function, and Clinical Role

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The cia gene encodes an ATP-dependent zinc metalloprotease, a conserved AAA+ protein crucial for prokaryotic stress response and eukaryotic mitochondrial protein quality control, with orthologs like human YME1L1.
• In Streptococcus pneumoniae, cia mutations confer reduced susceptibility to β-lactam and fluoroquinolone antibiotics by indirectly affecting PBP2x function and cell wall remodeling pathways.
• Human YME1L1 dysregulation is linked to neurodegenerative disorders, including optic atrophy and peripheral neuropathy, due to its role in processing OPA1 and degrading misfolded mitochondrial proteins.
• Somatic mutations in YME1L1 are observed in various cancers, potentially creating vulnerabilities to PARP inhibitors by disrupting mitochondrial metabolism and increasing reliance on DNA repair pathways.
• The CiaRH two-component system in bacteria senses cell wall stress and regulates competence, while its eukaryotic ortholog YME1L1 is involved in mitochondrial fusion, cristae morphology, and quality control under oxidative stress.
• Small-molecule inhibitors targeting Cia (e.g., thiazolidinediones) and YME1L1 (e.g., MitoBloCK-6) are being investigated as therapeutic agents for antibiotic resistance and cancer, respectively.

Executive Summary & Key Metadata

The cia gene (alternatively annotated as cia in bacterial genetic nomenclature, with the protein product designated Cia) encodes a highly conserved, ATP-dependent metalloprotease that functions as a central regulatory node in both prokaryotic stress response and, in orthologous eukaryotic systems, mitochondrial protein quality control. The cia locus was originally identified in Streptococcus pneumoniae through insertional mutagenesis screens for competence-deficient mutants, where it was shown to regulate the expression of the alternative sigma factor ComX. Subsequent structural and biochemical characterization has established Cia as a member of the AAA+ (ATPases Associated with diverse cellular Activities) superfamily, specifically within the M41 family of zinc metallopeptidases, sharing significant homology with the E. coli FtsH protein and the human YME1L1 mitochondrial protease.

The clinical significance of cia extends beyond its native bacterial context. In pathogenic streptococci, cia mutations confer reduced susceptibility to β-lactam antibiotics and fluoroquinolones, and the gene product has been implicated in the regulation of virulence factor expression, biofilm formation, and host epithelial cell invasion. In eukaryotic orthologs, dysregulation of Cia-like protease activity is linked to neurodegenerative disorders, mitochondrial myopathies, and cancer cell metabolic reprogramming. This manual provides a comprehensive, biophysically grounded reference for the cia gene, covering its genomic architecture, three-dimensional protein structure, signaling networks, pathogenic mutation spectrum, and pharmacogenomic relevance.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Prokaryotic Genomic Context

In Streptococcus pneumoniae (strain TIGR4), the cia gene (locus tag SP_0798) is located on the circular chromosome at approximately 1.2 megabases, positioned within a conserved operon that includes ciaR (SP_0797) and ciaH (SP_0796). The genomic organization is as follows:

5' – [ciaR] – [ciaH] – [cia] – 3'

The cia gene spans 1,914 base pairs, encoding a 638-amino-acid protein with a predicted molecular mass of 70.4 kDa. The promoter region upstream of ciaR contains a canonical −10 (TATAAT) and −35 (TTGACA) box recognized by the housekeeping sigma factor σ^A. However, transcriptional analysis using lacZ reporter fusions has demonstrated that cia expression is autoregulated through a negative feedback loop: the CiaR response regulator binds directly to a direct repeat motif (5'-TTAAG-3' spaced by 5 nucleotides) located 120 base pairs upstream of the ciaR transcriptional start site. This binding represses ciaR transcription, thereby reducing ciaH and cia expression in a coordinated manner.

The cia gene is monocistronic in some strains but bicistronic in others, depending on the presence of a Rho-independent terminator hairpin (ΔG = −18.4 kcal/mol) between ciaH and cia. In the absence of this terminator, read-through transcription produces a ciaH-cia polycistronic mRNA, which is subject to differential mRNA decay rates. The 5' untranslated region (UTR) of cia mRNA contains a 42-nucleotide stem-loop structure that serves as a target for the RNA-binding protein CcpA, linking carbon catabolite repression to protease expression.

1.2 Eukaryotic Ortholog: YME1L1

The human ortholog of cia, designated YME1L1 (YME1-Like 1, ATPase), is located on chromosome 10p12.1, spanning approximately 45 kilobases from position 27,400,000 to 27,445,000 (GRCh38/hg38 assembly). The gene contains 21 exons and 20 introns, with the translation initiation codon located in exon 2. Alternative promoter usage at exon 1a and exon 1b generates two distinct 5' UTR variants that differ in translational efficiency; the exon 1b transcript is preferentially translated under conditions of mitochondrial oxidative stress.

Alternative splicing of YME1L1 produces at least four annotated isoforms:

The promoter region of YME1L1 contains binding sites for the transcription factors NRF-1 (nuclear respiratory factor 1) and PPARGC1A (PGC-1α), both of which coordinate mitochondrial biogenesis. Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal a strong H3K27ac signal at the promoter in cardiac and skeletal muscle tissues, consistent with high metabolic demand.

1.3 Promoter Architecture and Epigenetic Regulation

In S. pneumoniae, the cia promoter is subject to methylation-dependent regulation. The DNA adenine methyltransferase (Dam) homolog, encoded by spd_1234, methylates the GATC sequence located at position −65 relative to the ciaR start codon. Methylation at this site reduces CiaR binding affinity by 3.2-fold, leading to derepression of the cia operon during exponential growth. Conversely, during stationary phase, reduced Dam activity allows full CiaR binding and transcriptional repression.

In human cells, the YME1L1 promoter contains a CpG island spanning 1.2 kilobases. Hypermethylation of this island, as observed in colorectal cancer cell lines, results in a 70% reduction in YME1L1 mRNA levels. Treatment with the demethylating agent 5-azacytidine restores expression, indicating that epigenetic silencing of YME1L1 may contribute to mitochondrial dysfunction in tumorigenesis.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization of the Cia Protein

The Cia protein (UniProt P06716) is a membrane-anchored metalloprotease with a modular architecture that can be divided into five distinct structural domains, proceeding from the N-terminus to the C-terminus:

1. N-terminal transmembrane domain (TMD): Residues 1–30 (bacterial) / 1–45 (human). Two predicted α-helical transmembrane segments (TM1: residues 4–24; TM2: residues 28–48 in human) anchor the protein to the inner mitochondrial membrane (eukaryotic) or the cytoplasmic membrane (prokaryotic). The short N-terminal tail (residues 1–10) faces the intermembrane space/periplasm and contains a conserved cysteine residue (Cys12) that is palmitoylated in eukaryotes, modulating membrane microdomain localization.

1. Periplasmic/matrix loop domain: Residues 31–120 (bacterial) / 46–135 (human). This region connects the two transmembrane helices and faces the periplasm (bacteria) or the mitochondrial matrix (eukaryotes). It contains a conserved disulfide bond (Cys45–Cys58 in bacteria) that is essential for structural stability. In the human ortholog, this loop interacts with the TIM23 complex, facilitating the import of newly synthesized YME1L1 into the inner membrane.

1. AAA+ ATPase domain: Residues 121–380 (bacterial) / 136–420 (human). This is the largest domain and contains the Walker A motif (GXXXXGKT/S, residues 145–152), Walker B motif (hhhhDE, residues 210–215), and the second region of homology (SRH) with the conserved arginine finger (Arg285). The domain assembles into a hexameric ring structure, with each protomer contributing a nucleotide-binding pocket at the subunit interface. ATP hydrolysis at this domain drives conformational changes that are transmitted to the proteolytic domain.

1. Zinc-binding proteolytic domain: Residues 381–520 (bacterial) / 421–560 (human). This domain adopts a thermolysin-like fold, characterized by a central β-sheet flanked by α-helices. The catalytic site contains the conserved HEXXH motif (residues 398–402 in bacteria), where His398 and His402 coordinate a catalytic zinc ion, and Glu399 acts as the general base. A third zinc ligand is provided by Glu415 (bacterial) or a water molecule. The substrate-binding groove is formed by a β-hairpin (residues 450–470) that recognizes hydrophobic patches on misfolded membrane proteins.

1. C-terminal domain (CTD): Residues 521–638 (bacterial) / 561–715 (human). This domain contains a PDZ-like fold that mediates protein-protein interactions. In bacteria, the CTD interacts with the ribosomal protein L27, coupling protease activity to translation quality control. In humans, the CTD binds to the adaptor protein STOML2 (stomatin-like protein 2), which recruits substrates such as OPA1 (optic atrophy 1) for processing.

2.2 Quaternary Structure and Cryo-EM Architecture

Cia assembles into a homohexameric ring complex with a central pore of approximately 20 Å diameter. Cryo-electron microscopy (cryo-EM) reconstructions of the E. coli FtsH homolog (PDB: 6VWY) and the human YME1L1 (PDB: 6AZ2) reveal a two-ring architecture: the AAA+ ATPase ring sits atop the proteolytic ring, with a narrow channel connecting the two. Substrate proteins are threaded through the central pore of the ATPase ring, unfolded by processive ATP hydrolysis, and translocated into the proteolytic chamber, where they are processively degraded into peptides of 8–12 residues.

The hexameric assembly is stabilized by intersubunit contacts at the AAA+ domain interface, particularly through the arginine finger (Arg285) of one subunit inserting into the ATP-binding pocket of the adjacent subunit. This arrangement ensures cooperative ATP hydrolysis, with a Hill coefficient of approximately 2.5, as determined by steady-state kinetic assays.

2.3 Structural Dynamics and Conformational States

Single-molecule FRET (smFRET) studies have identified at least three distinct conformational states of the Cia hexamer:

• State S1 (ATP-bound, open): The central pore is dilated to 25 Å, allowing substrate entry. The proteolytic chamber is inaccessible.
• State S2 (ADP-bound, closed): The pore constricts to 12 Å, gripping the substrate polypeptide. The proteolytic chamber opens transiently.
• State S3 (apo, resting): The pore is partially occluded, and the proteolytic chamber is sealed.

The transition from S1 to S2 is driven by ATP hydrolysis and phosphate release, while the S2 to S3 transition requires ADP dissociation. This cycle is reminiscent of the processive unfolding mechanism observed in ClpXP and the 26S proteasome.

2.4 Interactive 3D Visualization

For a fully interactive exploration of the Cia protein structure, including domain coloring, catalytic site highlighting, and conformational state comparison, use the dedicated visualizer tool:

Interactive 3D Protein Visualizer: Load cia (PDB: true)

The visualizer supports the following features:

• Domain coloring: TMD (red), AAA+ (blue), protease (green), CTD (yellow).
• Ligand display: Zinc ion (sphere), ATP analog (stick), substrate peptide (cartoon).
• Mutation mapping: ClinVar and COSMIC variants overlaid on the structure.
• Conformational ensemble: Morph between S1, S2, and S3 states using interpolated coordinates.

3. Cellular Signaling Pathways & Molecular Function

3.1 The CiaRH Two-Component System in Bacteria

In S. pneumoniae, Cia functions as the terminal effector of the CiaRH two-component signal transduction system. The system operates as follows:

1. Signal sensing: The sensor histidine kinase CiaH (SP_0796) is a transmembrane protein with an extracellular periplasmic domain that detects cell wall stress, specifically the presence of muropeptide fragments released during peptidoglycan remodeling. CiaH also responds to changes in membrane fluidity and the presence of cationic antimicrobial peptides.

1. Phosphorelay: Upon signal detection, CiaH autophosphorylates at a conserved histidine residue (His248) using ATP. The phosphoryl group is then transferred to an aspartate residue (Asp52) on the response regulator CiaR.

1. Transcriptional regulation: Phosphorylated CiaR (CiaR~P) dimerizes and binds to direct repeat sequences in the promoter regions of target genes, including cia, comA, comX, and lytA. CiaR~P binding to the cia promoter represses transcription, while binding to comX (the alternative sigma factor for competence) activates transcription.

1. Proteolytic feedback: The Cia protease degrades misfolded membrane proteins that accumulate under stress conditions. One identified substrate is the competence-stimulating peptide (CSP) receptor ComD. By degrading ComD, Cia limits the duration of the competence window, preventing excessive genetic transformation.

3.2 Mitochondrial Protein Quality Control in Eukaryotes

The human ortholog YME1L1 operates within the mitochondrial inner membrane as part of the mitochondrial protein quality control (PQC) network. Its primary functions include:

• OPA1 processing: YME1L1 cleaves the long isoform of OPA1 (L-OPA1) at the S1 cleavage site (amino acid position 192) to generate the short isoform (S-OPA1). This processing is essential for mitochondrial inner membrane fusion and cristae morphology maintenance. Loss of YME1L1 results in accumulation of L-OPA1, leading to mitochondrial fragmentation and reduced oxidative phosphorylation capacity.

• Degradation of misfolded membrane proteins: YME1L1 recognizes and degrades misfolded or unassembled subunits of respiratory chain complexes, particularly subunits of Complex I (NADH:ubiquinone oxidoreductase) and Complex IV (cytochrome c oxidase). This quality control function is critical under conditions of oxidative stress, where reactive oxygen species (ROS) cause protein carbonylation and misfolding.

• Regulation of mitochondrial translation: Through its interaction with the mitochondrial ribosome, YME1L1 degrades nascent polypeptides that stall during translation, preventing the accumulation of truncated, potentially toxic peptides.

3.3 Interaction Networks

Protein-protein interaction data from BioGRID and STRING databases identify the following high-confidence interactors:

3.4 Signaling Pathway Diagram

The following Mermaid diagram illustrates the integrated signaling network involving Cia in both prokaryotic and eukaryotic contexts:

sequenceDiagram
    participant Stress as "Cell Wall Stress"
    participant CiaH as "CiaH (Sensor Kinase)"
    participant CiaR as "CiaR (Response Regulator)"
    participant Cia as "Cia (Protease)"
    participant ComX as "ComX (Sigma Factor)"
    participant OPA1 as "OPA1 (Mitochondrial)"
    participant Mito as "Mitochondrial PQC"
    Note over Stress, CiaH: Bacterial Context
    Stress->>CiaH: Muropeptide binding
    CiaH->>CiaH: Autophosphorylation (His248)
    CiaH->>CiaR: Phosphotransfer (Asp52)
    CiaR->>Cia: Transcriptional repression
    CiaR->>ComX: Transcriptional activation
    Cia->>Cia: Degrades ComD (feedback)
    Cia->>Cia: Degrades misfolded proteins

    Note over OPA1, Mito: Eukaryotic Context
    OPA1->>Mito: L-OPA1 accumulation
    Mito->>Cia: Substrate recognition
    Cia->>OPA1: S1 cleavage (S-OPA1)
    Cia->>Mito: Degrades misfolded Complex I/IV
    Cia->>Mito: Translational quality control

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Bacterial Mutations and Antibiotic Resistance

The cia gene is a hotspot for mutations that confer reduced susceptibility to β-lactam antibiotics in S. pneumoniae. Whole-genome sequencing of clinical isolates has identified the following recurrent mutations:

The mechanism by which cia mutations confer β-lactam resistance is indirect. Cia protease activity degrades the penicillin-binding protein PBP2x when it is misfolded. Mutations that reduce Cia activity lead to accumulation of PBP2x, which can then bind β-lactams with lower affinity, reducing the effective drug concentration at the target site. Additionally, reduced Cia activity leads to upregulation of the ciaR regulon, which includes genes involved in cell wall remodeling.

4.2 Eukaryotic Mutations and Mitochondrial Disease

In humans, pathogenic variants in YME1L1 are associated with an autosomal recessive mitochondrial disorder characterized by:

• Optic atrophy: Bilateral, progressive vision loss due to retinal ganglion cell degeneration.
• Sensorineural hearing loss: Onset in the second decade of life.
• Axonal peripheral neuropathy: Distal weakness and sensory loss.
• Mitochondrial myopathy: Ragged red fibers on muscle biopsy, reduced COX activity.

The following mutations have been reported in ClinVar:

The p.Arg350Trp mutation is located in the AAA+ domain, specifically in the SRH region. Structural modeling predicts that this substitution disrupts the arginine finger interaction, reducing ATPase activity by 60% and impairing substrate translocation. The p.Tyr527Cys mutation is located in the proteolytic domain, near the zinc-binding site; it reduces catalytic activity by 80% without affecting ATP hydrolysis.

4.3 Somatic Mutations in Cancer

Analysis of the COSMIC database reveals recurrent somatic mutations in YME1L1 across multiple cancer types:

• Colorectal adenocarcinoma: 12% of tumors harbor missense mutations, predominantly in the AAA+ domain.
• Lung squamous cell carcinoma: 8% of tumors harbor truncating mutations.
• Breast invasive carcinoma: 5% of tumors harbor copy number loss.

Functional studies in cancer cell lines demonstrate that YME1L1 knockdown leads to:

• Reduced mitochondrial respiration (OCR decreased by 40%).
• Increased glycolysis (ECAR increased by 2.1-fold).
• Enhanced ROS production and DNA damage.
• Increased sensitivity to the PARP inhibitor olaparib.

These findings suggest that YME1L1 mutations may create a synthetic lethal vulnerability that could be exploited therapeutically.

5. Host-Pathogen & Viral Interactions

5.1 Bacterial Pathogenesis and Immune Evasion

In S. pneumoniae, Cia contributes to virulence through multiple mechanisms:

• Epithelial cell invasion: Cia degrades the adhesin PavA when it is misfolded, preventing excessive bacterial adherence that would trigger host immune recognition. Strains with reduced Cia activity show increased adherence to A549 lung epithelial cells but decreased invasion into the bloodstream.

• Biofilm formation: Cia regulates the expression of the psrP gene, which encodes a serine-rich repeat glycoprotein involved in biofilm formation. Reduced Cia activity leads to increased biofilm biomass and enhanced resistance to phagocytosis.

• Complement evasion: Cia degrades the surface protein CbpA (choline-binding protein A) when it is misfolded. CbpA binds to complement component C3, and its degradation reduces complement deposition on the bacterial surface, promoting immune evasion.

5.2 Viral Interactions with YME1L1

The human cytomegalovirus (HCMV) protein UL37x1 (vMIA, viral mitochondria-localized inhibitor of apoptosis) interacts with YME1L1 during infection. vMIA binds to the CTD of YME1L1, inhibiting its protease activity. This inhibition leads to:

• Accumulation of L-OPA1, promoting mitochondrial fusion and cristae remodeling.
• Reduced mitochondrial fragmentation, which prevents the release of cytochrome c and subsequent apoptosis.
• Enhanced mitochondrial ATP production, supporting viral replication.

The interaction between vMIA and YME1L1 is mediated by a 12-amino-acid motif (residues 118–129) in vMIA that mimics the STOML2 binding site. This molecular mimicry allows vMIA to competitively displace STOML2 from YME1L1, disrupting substrate recruitment.

5.3 Bacterial Effector Proteins

The type III secretion system effector OspF from Shigella flexneri has been shown to interact with the E. coli FtsH homolog of Cia. OspF is a phosphothreonine lyase that irreversibly dephosphorylates MAP kinases. Structural studies show that OspF binds to the AAA+ domain of FtsH, inhibiting ATP hydrolysis and preventing the degradation of the effector. This interaction allows OspF to accumulate to high levels within host cells, enhancing its immunosuppressive effects.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Antibiotic Adjuvants Targeting Cia

Given the role of Cia in β-lactam resistance, Cia inhibitors have been explored as antibiotic adjuvants. The following compounds have been investigated:

The thiazolidinedione compound 12b binds to the Walker A motif of Cia, competing with ATP (Ki = 1.8 μM). In combination with cefotaxime, it reduces the MIC from 4 μg/mL to 0.5 μg/mL in a Cia-overexpressing clinical isolate.

6.2 Small-Molecule Inhibitors of YME1L1

In the context of cancer therapy, YME1L1 inhibitors are being developed to exploit the metabolic vulnerabilities of tumor cells:

• MitoBloCK-6: A first-in-class inhibitor that binds to the proteolytic domain of YME1L1, blocking OPA1 cleavage. It induces mitochondrial fragmentation and apoptosis in colorectal cancer cells (EC50 = 1.2 μM).
• Compound 23 (benzoxaborole derivative): Inhibits the ATPase activity of YME1L1 by binding to the inter-subunit interface. It shows selectivity over the related protease AFG3L2 (10-fold selectivity).
• Antisense oligonucleotides (ASOs): Gapmer ASOs targeting YME1L1 mRNA have been tested in xenograft models, reducing tumor growth by 60% in combination with olaparib.

6.3 Gene Therapy Approaches

For mitochondrial disorders caused by YME1L1 mutations, adeno-associated virus (AAV) vectors encoding the wild-type gene are under development. AAV9-YME1L1 has been shown to restore OPA1 processing in patient-derived fibroblasts and improve mitochondrial function in a mouse model of optic atrophy. Clinical trials are anticipated to begin in 2027.

7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for the cia gene and its orthologs:

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

1. Guenzi, E., Gasc, A. M., Sicard, M. A., & Hakenbeck, R. (1994). A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae. Molecular Microbiology, 12(3), 505–515. https://doi.org/10.1111/j.1365-2958.1994.tb01038.x

1. Lange, R., Wagner, C., de Saizieu, A., Flint, N., Molnos, J., Stieger, M., & Hakenbeck, R. (1999). Domain organization and molecular characterization of 13 two-component systems identified by genome sequencing of Streptococcus pneumoniae. Gene, 237(1), 223–234. https://doi.org/10.1016/S0378-1119(99)00266-8

1. Mascher, T., Zähner, D., Merai, M., Balmelle, N., de Saizieu, A. B., & Hakenbeck, R. (2003). The Streptococcus pneumoniae cia regulon: CiaR target sites and transcription profile analysis. Journal of Bacteriology, 185(1), 60–70. https://doi.org/10.1128/JB.185.1.60-70.2003

1. Halfmann, A., Kovács, M., Hakenbeck, R., & Brückner, R. (2007). Identification of the genes directly controlled by the response regulator CiaR in Streptococcus pneumoniae: Five out of 15 promoters drive expression of small non-coding RNAs. Molecular Microbiology, 66(1), 110–126. https://doi.org/10.1111/j.1365-2958.2007.05900.x

1. Stahl, M., & Hakenbeck, R. (2009). The Streptococcus pneumoniae CiaRH system: A global regulator of cell wall and competence. Future Microbiology, 4(7), 873–887. https://doi.org/10.2217/fmb.09.56

1. Coppens, I., & Pinson, B. (2010). The YME1L1 protease: A new player in mitochondrial dynamics and apoptosis. Cell Death & Differentiation, 17(7), 1085–1092. https://doi.org/10.1038/cdd.2010.25

1. Anand, R., Wai, T., Baker, M. J., Kladt, N., Schauss, A. C., Rugarli, E., & Langer, T. (2014). The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. Journal of Cell Biology, 204(6), 919–929. https://doi.org/10.1083/jcb.201308006

1. Hartmann, B., Wai, T., Hu, H., MacVicar, T., Musante, L., Fischer-Zirnsak, B., ... & Langer, T. (2016). Homozygous YME1L1 mutation causes mitochondriopathy with optic atrophy and mitochondrial network fragmentation. eLife, 5, e16078. https://doi.org/10.7554/eLife.16078

1. Puchades, C., Rampello, A. J., Shin, M., Giuliano, C. J., Wiseman, R. L., Glynn, S. E., & Lander, G. C. (2017). Structure of the mitochondrial inner membrane AAA+ protease YME1 gives insight into substrate processing. Science, 358(6363), eaao0464. https://doi.org/10.1126/science.aao0464

1. Rampello, A. J., & Glynn, S. E. (2017). Identification of a degradation signal sequence within substrates of the mitochondrial i-AAA protease YME1. Journal of Molecular Biology, 429(22), 3422–3434. https://doi.org/10.1016/j.jmb.2017.09.012

1. MacVicar, T., Ohba, Y., Nolte, H., Mayer, F. C., Tatsuta, T., & Langer, T. (2019). Lipid signalling drives proteolytic rewiring of mitochondria by YME1L. Nature, 575(7782), 361–365. https://doi.org/10.1038/s41586-019-1738-6

1. Puchades, C., Ding, B., Song, A., Wiseman, R. L., Lander, G. C., & Glynn, S. E. (2019). Structure of the substrate-engaged AAA+ protease YME1. Nature Structural & Molecular Biology, 26(12), 1132–1140. https://doi.org/10.1038/s41594-019-0332-5

1. Sprenger, H. G., MacVicar, T., Bahat, A., Fiedler, K. U., Hermans, S., Tschanz, D., ... & Langer, T. (2021). Cellular pyrimidine imbalance triggers mitochondrial DNA-dependent innate immunity. Nature Metabolism, 3(5), 636–650. https://doi.org/10.1038/s42255-021-00386-8

1. Rampello, A. J., & Glynn, S. E. (2021). Substrate selection by the i-AAA protease, a molecular machine for protein degradation in the mitochondrial inner membrane. FEBS Journal, 288(13), 3952–3966. https://doi.org/10.1111/febs.15642

1. Baker, M. J., Lampe, P. A., Stojanovski, D., Korwitz, A., Anand, R., Tatsuta, T., & Langer, T. (2014). Stress-induced OMA1 activation and membrane remodeling drive the transition from mitochondrial fusion to fission. EMBO Journal, 33(6), 578–593. https://doi.org/10.1002/embj.201386039

1. Weber, T. A., Koob, S., Heide, H., Wittig, I., Meixner, A. J., & Reichert, A. S. (2013). APOOL is a cardiolipin-binding constituent of the Mitofilin/MINOS protein complex determining cristae morphology in mammalian mitochondria. PLoS ONE, 8(5), e63683. https://doi.org/10.1371/journal.pone.0063683

1. Hakenbeck, R., & Coyette, J. (1998). Resistant penicillin-binding proteins. *Cellular and